| BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Kateřina KUBÁČKOVÁ, Igor KISS, Milada ZEMANOVA, Ondrej FIALA, Ladislav DUŠEK, Rostislav VYZULA a Bohuslav MELICHAR. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. New York: ELSEVIER SCIENCE INC., 2014, roč. 32, č. 5, s. 569-575. ISSN 1078-1439. Dostupné z: https://dx.doi.org/10.1016/j.urolonc.2013.12.007. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1195775,
author = {Buchler, Tomas and Bortlíček, Zbyněk and Poprach, Alexandr and Kubáčková, Kateřina and Kiss, Igor and Zemanova, Milada and Fiala, Ondrej and Dušek, Ladislav and Vyzula, Rostislav and Melichar, Bohuslav},
article_location = {New York},
article_number = {5},
doi = {http://dx.doi.org/10.1016/j.urolonc.2013.12.007},
keywords = {Everolimus; mTOR; Renal cell carcinoma; Tyrosine kinase inhibitors; Therapy},
language = {eng},
issn = {1078-1439},
journal = {UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS},
title = {Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis},
volume = {32},
year = {2014}
}
TY - JOUR
ID - 1195775
AU - Buchler, Tomas - Bortlíček, Zbyněk - Poprach, Alexandr - Kubáčková, Kateřina - Kiss, Igor - Zemanova, Milada - Fiala, Ondrej - Dušek, Ladislav - Vyzula, Rostislav - Melichar, Bohuslav
PY - 2014
TI - Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
JF - UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
VL - 32
IS - 5
SP - 569-575
EP - 569-575
PB - ELSEVIER SCIENCE INC.
SN - 10781439
KW - Everolimus
KW - mTOR
KW - Renal cell carcinoma
KW - Tyrosine kinase inhibitors
KW - Therapy
N2 - Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on everolimus was associated with PFS on previous TKIs in patients receiving 1 but not 2 previous TKIs. Only 13% of 352 patients starting targeted therapy for mRCC in 2010 had received 3 sequential targeted agents by the data cutoff in March 2013. Conclusion: PFS on everolimus correlated with PFS on TKIs in patients pretreated with 1 but not 2 TKIs. Everolimus can be deferred to the third line without loss of efficacy or increased toxicity. However, only a minority of patients with mRCC starting targeted treatment can be expected to receive third-line therapy.
ER -
BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Kateřina KUBÁČKOVÁ, Igor KISS, Milada ZEMANOVA, Ondrej FIALA, Ladislav DUŠEK, Rostislav VYZULA a Bohuslav MELICHAR. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. \textit{UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}. New York: ELSEVIER SCIENCE INC., 2014, roč.~32, č.~5, s.~569-575. ISSN~1078-1439. Dostupné z: https://dx.doi.org/10.1016/j.urolonc.2013.12.007.
|
